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Abstract 
 
Objectives: To investigate the relationship between fetal major cardiac defects and markers 
of placental perfusion and function.  
 
Methods: This was a prospective screening study in singleton pregnancies at 11-13 weeks’ 
gestation. Uterine artery pulsatility index (UTPI), serum pregnancy associated plasma 
protein-A (PAPP-A) and placental growth factor (PLGF) were measured and the values were 
converted into multiples of the normal median (MoM). Median MoM values in fetuses with 
isolated major cardiac defects were compared to those in fetuses without major defects.  
 
Results: The 50,094 singleton pregnancies fulfilling the entry criteria included 49,898 
pregnancies with a normal cardiac anatomy and 196 (0.39%) with major congenital cardiac 
defects; 73 (37.2%) with conotruncal defects, 63 (32.1%) with left ventricular outflow tract 
(LVOT) defects and 60 (30.6%) with valvular defects. In the group of cardiac defects, 
compared to controls, there was lower median PAPP-A MoM (0.81 vs 1.00, p<0.0001) and 
PLGF MoM (0.78 vs 1.00, p<0.0001) but no significant difference in UTPI MoM (1.01 vs 
1.00, p=0.162). 
 
Conclusions: In pregnancies with isolated major cardiac defects there is evidence of 
placental dysfunction in the absence of impaired placental perfusion.  
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Introduction 
 
Congenital heart defects (CHD) are considered to be major if they require surgery or 
interventional cardiac catheterization within the first year of life, and such defects are often 
associated with fetal growth restriction (FGR).1-4 It is uncertain whether the cause of FGR is 
of placental origin or genetic as is the case with many fetal abnormalities.5-8 A study of 68 
cases of isolated major CHDs and 340 normal controls at 11-13 weeks’ gestation reported 
that in the CHD group maternal serum levels of placental growth factor (PLGF) were 
decreased, but there was no significant change in the levels of pregnancy associated 
plasma protein-A (PAPP-A) or uterine artery pulsatility index (UTPI); these findings 
suggested that in CHD there is evidence of impaired placental angiogenesis in the absence 
of impaired placental perfusion and function.9 
 
The objective of this study is to investigate further the relationship between isolated major 
CHDs and markers of placental perfusion and function.  
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Methods 
 
Study population 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for routine pregnancy care at 11+0-13+6 weeks’ gestation at 
King’s College Hospital and Medway Maritime Hospital, United Kingdom. This visit, included 
recording of maternal demographic characteristics and obstetric and medical history, 
measurement of maternal weight and height, ultrasound examination for the measurement of 
the fetal crown-rump length (CRL) to determine gestational age,10 measurement of the fetal 
nuchal translucency (NT) thickness, maternal serum PAPP-A and free ß-human chorionic 
gonadotropin for combined screening for fetal aneuploidies,11 examination of the fetal 
anatomy for the diagnosis of major fetal defects,12 and transabdominal colour Doppler 
ultrasound for the measurement of UTPI.13 The women were screened between March 2006 
and October 2015 and gave written informed consent to participate in the study, which was 
approved by the Ethics Committee.  
 
The policy in our hospitals was to offer routinely a second ultrasound examination at 20+0-
23+6 weeks. This scan was performed transabdominally and involved systematic detailed 
examination of the fetus, including a sweep through the heart in transverse plane to include 
the four-chamber view, outflow tracts and three vessel view of the heart and great vessels. 
All cases of suspected fetal abnormalities were examined by a fetal medicine specialist. 
Likewise, all cases of suspected fetal cardiac defect were examined by a fetal cardiologist. In 
addition, the cardiologists carried out fetal echocardiography at 11-14 weeks in those with 
nuchal translucency above the 99th centile and at 20 weeks in those with nuchal 
translucency between the 95th and 99th centiles. 
 
All neonates were examined by a pediatrician. Prenatal and neonatal findings were recorded 
in computerised databases. Data on pregnancy outcome from women who booked for 
obstetric care in our hospitals but delivered in other hospitals were obtained either from the 
maternity computerised records in these hospitals or the general medical practitioners of the 
women. 
 
Inclusion and exclusion criteria 
 
In this study we compared the measurements of serum PAPP-A and PLGF, fetal NT and 
UTPI at 11-13 weeks in pregnancies with major fetal cardiac defects and those resulting in 
live birth of phenotypically normal babies. We excluded all aneuploidies and non-cardiac 
defects diagnosed prenatally or in the neonatal period.  
 
We included all cases with major cardiac defects diagnosed by pediatric cardiologists either 
antenatally and / or in the neonatal period. Abnormalities suspected antenatally but not 
confirmed in the neonates were not included. In contrast, the prenatal diagnosis in cases of 
terminations and miscarriages at < 24 weeks or stillbirths at > 24 weeks were assumed to be 
correct because in these cases postmortem examination was not performed systematically. 
The following fetal cardiac defects were not included: firstly, ventricular septal defects 
because they are generally not considered to be major defects, secondly, right aortic arch, 
persistent left superior vena cava and aberrant right subclavian artery because these are 
variants of normal rather than true defects and thirdly, cardiac tumors developing during the 
second and third trimesters of pregnancy because these defects would not be expected to 
have any manifestations during the 11-13 weeks scan. 
 
We excluded all aneuploidies and non-cardiac defects diagnosed prenatally or in the 
neonatal period. We also excluded pregnancies with no abnormal fetal findings at the 11-13 
weeks scan and / or the 20-23 weeks scan which resulted in termination, miscarriage or 
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stillbirth and those lost to follow up. 
 
Classification of cardiac defects 
 
Major cardiac defects were subdivided into three groups as in a previous publication.9 First, 
conotruncal cardiac defects, which included tetralogy of Fallot, transposition of great arteries, 
double outlet right ventricle, and common arterial trunk. Second, left ventricular outflow tract 
(LVOT) defects, which included hypoplastic left heart syndrome, aortic stenosis, coarctation 
of aorta, and interrupted aortic arch. Third, valvular defects, which included atrioventricular 
septal defects, tricuspid stenosis, dysplasia or atresia, pulmonary stenosis or atresia, and 
Ebstein’s anomaly. 
 
Statistical analysis 
 
Data from continuous variables were expressed as medians and interquartile ranges and 
from categorical data as n (%). Comparison of the maternal characteristics between the 
outcome groups was by the χ2-square test or Fisher’s exact test for categorical variables 
and Mann-Whitney U-test for continuous variables, respectively. A p value of < 0.05 was 
considered significant. Post-hoc Bonferroni correction was used for multiple comparisons. 
 
The measured values of PAPP-A, PLGF and UTPI were log10 transformed to make their 
distributions Gaussian and each value was expressed as a multiple of the normal median 
(MoM) after adjustment for those characteristics that provide a substantial contribution to the 
log10 transformed value.14-16 The measured fetal NT was expressed as a difference from the 
expected normal mean for fetal CRL (delta value).17 Median MoM values of biomarkers were 
compared between outcome groups. We divided congenital cardiac defects into those with 
fetal NT< 3.5 and those with measurements ≥ 3.5 and compared the significant of difference 
in the biomarkers in each group. Non-parametric bivariate correlation analysis was used to 
examine the association between biomarkers in pregnancies with congenital cardiac defects 
and those with normal cardiac anatomy.  
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) was used for the data analyses. 
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Results 
 
Study population 
 
The 50,094 singleton pregnancies fulfilling the entry criteria included 49,898 pregnancies 
with a normal cardiac anatomy and 196 (0.4%) with major congenital cardiac defects; 73 
(37.2%) with conotruncal defects, 63 (32.1%) with LVOT defects and 60 (30.6%) with 
valvular abnormalities. The maternal and pregnancy characteristics in the outcome groups 
are compared in Table 1.  
 
Biomarkers in outcome groups 
 
In the cardiac defect group, compared to the normal cardiac anatomy group, the median 
PlGF MoM and PAPP-A MoM were lower, fetal delta NT was higher and UTPI MoM was not 
significantly different. In all the sub-groups of congenital cardiac defects, this trend was 
maintained with lower PLGF and PAPP-A MoMs, higher delta fetal NT but no significant 
difference in UTPI MoM (Table 2, Figure 1).  
 
A significant association between PlGF MoM and delta fetal NT was found in the group with 
cardiac defects but not in those without defects (Table 3). In fetuses with cardiac defects and 
increased NT PLGF MoM was significantly lower in those with increased NT, compared to 
those with normal NT (0.56 vs 0.83 MoM; p=0.007) (Figure 2); there was no significant 
difference in PAPP-A MoM between the two groups (0.84 vs 0.79 MoM; p=0.586). 
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Discussion 
 
Main findings of the study 
 
The findings of the study demonstrate that in pregnancies with major cardiac defects, 
compared to those with normal cardiac anatomy, serum PAPP-A and PlGF are significantly 
lower, but there is no significant difference in UTPI. These findings suggest that in fetal 
cardiac defects there is evidence of placental dysfunction in the absence of impairment in 
placental perfusion. In pregnancies with major cardiac defects, compared to those without, 
fetal NT is increased and in those with high NT serum PLGF is lower than in those with 
normal NT; this finding is compatible with that of a previous study which suggested a 
common pathophysiological mechanism for high NT and low PLGF.9 
 
The suggestion that in pregnancies with major cardiac defects there is placental dysfunction 
in the absence of impaired perfusion is supported by evidence from placental histological 
studies that in pregnancies with heart defects, compared to matched controls, there is 
significantly reduced placental weight, decreased number of terminal chorionic villi due with 
reduced proliferation and branching of fetal vasculature within the villi.18 This is different from 
pregnancies complicated by preeclampsia and fetal growth restriction where low serum 
PAPP-A and PLGF is accompanied by increased UTPI.19-22 
 
Strengths and limitations 
 
The strengths of this screening study are first, examination of a large population of pregnant 
women attending for routine assessment at 11-13 weeks’ gestation, second, prospective 
recording of data regarding cardiac defects based on a specific protocol which includes a 
detailed screening examination, review by fetal cardiologist in those with suspected 
abnormalities and neonatal examination by a pediatrician in all cases; third, use of a specific 
methodology and appropriately trained doctors to obtain measurements of UTPI, fourth, 
availability of accurate measurements of  PAPP-A and PlGF in the study population and fifth, 
expression of the values of biomarkers as MoMs after adjustment for factors that affect the 
measurements.  
 
Comparison with other studies 
 
Our findings that in pregnancies with fetal cardiac defects first, serum PLGF is reduced, fetal 
NT is increased and UTPI is not significantly altered and second, there is a significant 
association between PLGF and NT are similar to those of a previous case-control study of 
68 pregnancies with major cardiac defects and 340 controls.9 In the previous study serum 
PAPP-A was reduced but not significantly so, presumably because of the small number of 
cases. Another difference between the studies is that we found PLGF to be reduced in all 
three types of cardiac defects, whereas in the previous study it was reduced in conotruncal 
and valvular defects but not in LVOT defects.9  
 
Conclusion 
 
The findings of our study suggest that in pregnancies with major cardiac defects there is 
placental dysfunction from as early as 11-13 weeks’ gestation in the absence of impaired 
placental perfusion. 
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Table 1. Maternal and pregnancy characteristics in fetuses with congenital cardiac defect, stratified according to sub-groups, compared to 
those with normal cardiac anatomy. 
 
Maternal characteristics No cardiac defect(n=49,898) 
All cardiac defects
(n=196) 
Conotruncal defects
(n=73) 
LVOT defects
(n=63) 
Valvular defects
(n=60) 
Age, median (IQR) 31.2 (26.7-34.8) 31.7 (26.1-36.1) 30.1 (24.7-35.2) 32.3 (28.9-36.3) 32.6 (26.5-36.5) 
Weight, median (IQR) 66.9 (59.1-77.7) 67.0 (58.5-78.9) 68.0 (59.0-86.0) 67.0 (57.2-77.6) 65.6 (59.9-76.9) 
Height, median (IQR) 1.65 (1.60-1.69) 1.65 (1.59-1.70) 1.65 (1.58-1.70) 1.67 (1.57-1.70) 1.65 (1.60-1.70) 
Racial origin      
     Caucasian, n (%) 36,327 (72.8) 146 (74.5) 53 (72.6) 49 (77.8) 44 (73.3) 
     Afro-Caribbean, n (%) 8,823 (17.7) 33 (16.8) 11 (15.1) 9 (14.3) 13 (21.7) 
     South Asian, n (%) 2,296 (4.6) 9 (4.6) 3 (4.1) 3 (4.8) 3 (5.0) 
     East Asian, n (%) 1,123 (2.3) 5 (2.6) 4 (5.5) 1 (1.6) 0 
     Mixed, n (%) 1,329 (2.7) 3 (1.5) 2 (2.7) 1 (1.6) 0 
Method of conception      
     Spontaneous, n (%) 48,317 (96.8) 189 (96.4) 73 (100.0) 61 (96.8) 55 (91.7) 
     Assisted conception, n (%) 1,581 (3.2) 7 (3.6) 0 2 (3.2) 5 (8.3) 
Cigarette smoking, n (%) 4,595 (9.2) 16 (8.2) 7 (9.6) 5 (7.9) 4 (6.7) 
Chronic hypertension, n (%) 735 (1.5) 2 (1.0) 1 (1.4) 0 1 (1.7) 
SLE / APS, n (%) 114 (0.2) 0 0 0 0 
Diabetes mellitus, n (%) 435 (0.9) 5 (2.6) * 3 (4.1) 2 (3.2) 0 
Nulliparous, n (%) 25,003 (50.1) 101 (51.5) 40 (54.8) 32 (50.8) 29 (48.3) 
Inter-pregnancy interval, median (IQR) 3.0 (2.0-4.9) 2.8 (1.8-3.9) 2.2 (1.6-3.8) 2.8 (1.9-3.3) 3.2 (1.9-5.0) 
 
Post hoc Bonferroni correction for multiple comparisons; * = p< 0.0167; LVOT = left ventricular outflow tract; IQR = interquartile range; 
SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome.  
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Table 2. Median and interquartilie range of biomarkers in fetuses with 
congenital cardiac defects compared to those with a normal cardiac anatomy. 
 
Marker No cardiac defect (n=49,898) 
All cardiac defects 
(n=196) 
Conotruncal defects 
(n=73) 
LVOT defects 
(n=63) 
Valvular defects 
(n=60) 
Serum PAPP-A MoM 1.00 (0.69-1.42) 0.81 (0.52-1.27)** 0.73 (0.57-1.18)* 0.73 (0.44-1.29)* 0.90 (0.55-1.32) 
Serum PlGF MoM 1.00 (0.77-1.29) 0.78 (0.56-1.07)** 0.75 (0.55-0.97)** 0.80 (0.56-1.19)* 0.74 (0.61-1.17)* 
UTPI MoM 1.00 (0.81-1.22) 1.01 (0.83-1.26) 0.97 (0.81-1.28) 1.05 (0.84-1.29) 1.00 (0.89-1.25) 
Delta fetal NT 0.00 (-0.20-0.22) 0.28 (-0.06-0.86)** 0.19 (-0.11-0.68)** 0.47 (-0.02-0.89)** 0.24 (-0.04-0.96)** 
 
Significance value * p<0.01; ** p<0.001; post hoc Bonferroni correction for multiple 
comparisons; LVOT = Left ventricular outflow tract; PAPP-A = pregnancy associated plasma 
protein-A;  PLGF = placental growth factor; UTPI = uterine artery pulsatility index ; NT = 
nuchal translusency; MoM = Multiple of normal median. 
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Table 3. Correlations between biophysical and biochemical markers in fetuses with and 
without congenital cardiac defects.  
 
Marker 
Congenital cardiac defects 
Serum PlGF MoM Serum PAPP-A MoM Uterine artery PI MoM Delta fetal NT 
Serum PlGF MoM - r = 0.340; p<0.0001 r = -0.232; p = 0.001 r = -0.151; p = 0.035 
Serum PAPP-A MoM  - r = -0.217; p = 0.002 r = -0.010; p = 0.893 
Uterine artery PI MoM   - r = -0.078; p = 0.278 
Delta fetal NT    - 
 
Normal cardiac anatomy 
Serum PlGF MoM Serum PAPP-A MoM Uterine artery PI MoM Delta fetal NT 
Serum PlGF MoM - r = 0.287; p<0.0001 r = -0.135; p<0.0001 r = 0.004; p = 0.358 
Serum PAPP-A MoM  - r = -0.152; p<0.0001 r = 0.020; p <0.0001 
Uterine artery PI MoM   - r = -0.006; p = 0.203 
Delta fetal NT    - 
 
PAPP-A = pregnancy associated plasma protein-A;  PLGF = placental growth factor; UTPI = uterine 
artery pulsatility index ; NT = nuchal translusency; MoM = Multiple of normal median. 
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